Monoclonal antibodies were developed against human pancreatic prophospholipase A
2 (proPLA
2). They had high affinity for proPLA
2 and small cross reactivities with human pancreatic phospholipase A
2 (PLA
2). By S-Sepharose ion-exchange chromatography combined with radioimmunoassay for proPLA
2 and that for PLA
2 both using monoclonal antibodies, proPLA
2 and PLA
2 in human sera could be separated and measured. In healthy individuals, proPLA
2 proved to be the major form of the enzyme, while two out of three patients with pancreatitis showed a larger proportion of PLA
2, which may be an indication of the severity of the pancreatitis. In patients with pancreatic cancer and chronic renal failure, proPLA
2 remained in larger proportion in spite of the very high radioimmunoassay level of PLA
2. The concentrations of both proPLA
2 and PLA
2 in human sera could be estimated by a combination of the two radioimmunoassay systems, suggesting that this combination radioimmunoassay could be used to more precisely diagnose pancreatitis and other diseases exhibiting high levels of immunoreactive PLA
2 than a single radioimmunoassay system.
抄録全体を表示